-
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated H Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1 Preliminary activit...资讯2024-09-10
最热
推荐
- 防范于心反诈于行:南京移动防电诈宣传进社区
- 卡伦益生菌:45年匠心研发,有效改善易敏体质
- 加快打造优质产能,比克大圆柱电池树立行业新标杆
- 让世界品尝中国丨喜家德水饺连续六次与达沃斯晚宴携手
- 奥运火炬的三次传递 品牌精神的传承赓续丨陈忠伟董事长巴黎传递奥运圣火
- Sidra Capital Launches Singapore-based VCC for Cross-Border Commodity Supply Chain Investments
- NetApp扩展智能数据基础设施功能,为战略云工作负载提供支持
- 王自如被强制执行3383万
- “普聚金融服务 惠泽千企万户”平安养老险陕西分公司积极开展普惠金融推进月活动
- 中国塑形行业的崛起:观塑品牌,如何打破偏见成为塑形行业的标杆